Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Castle Biosciences (CSTL) Preferred Stock Liabilities (2018 - 2019)

Castle Biosciences' Preferred Stock Liabilities history spans 2 years, with the latest figure at $1.5 million for Q2 2019.

On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $1.5 million in Q2 2019 year-over-year; TTM through Jun 2019 was $1.5 million, a 0.0% change, with the full-year FY2018 number at $27.2 million, changed N/A from a year prior.
Preferred Stock Liabilities hit $1.5 million in Q2 2019 for Castle Biosciences, down from $45.1 million in the prior quarter.
Over the last five years, Preferred Stock Liabilities for CSTL hit a ceiling of $45.1 million in Q1 2019 and a floor of $1.5 million in Q1 2018.